Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 47 Gastrointestinal 42 Head & Neck 11 Gynecologic 11 Thoracic 10 Other hematologic neoplasm 9 Tumor-Agnostic 8 Genitourinary 6 Lymphoid 5 Endocrine 3 CNS 3 Sarcoma 2 Plasma cell 1 Other solid neoplasm 1 Other neoplasm 1 Other 1 NET 1 Dermatologic 1 Classical hematology 1

Conditions

Osteolysis 1 Multiple Myeloma 1 Motor Activity 1

Interventions

Dexamethasone 881 Bortezomib 478 Lenalidomide 467 Cyclophosphamide 367 Melphalan 275 Calcium Dobesilate 264 daratumumab 240 pomalidomide 215 carfilzomib 188 fludarabine phosphate 141 fludarabine 137 Thalidomide 125 Peripheral Blood Stem Cell Transplantation 120 Filgrastim 115 ixazomib 94 Mycophenolic Acid 91 Granulocyte Colony-Stimulating Factor 90 Busulfan 89 Whole-Body Irradiation 88 dexamethasone acetate 87 Tacrolimus 79 dexamethasone 21-phosphate 74 isatuximab 68 Cyclosporine 68 auricularum 67 Prednisone 67 elotuzumab 63 belantamab mafodotin 59 Antilymphocyte Serum 56 Etoposide 53

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Control Groups × Plasma cell × Clear all

NCT07026799 2025-06-18

GMMG-HD8-INDEX

University Hospital Heidelberg

Phase NA Active not recruiting

Motor Activity, Multiple Myeloma, Osteolysis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡